Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etonogestrel implant - Merck & Co

Drug Profile

Etonogestrel implant - Merck & Co

Alternative Names: 3-Keto-desogestrel; 3-Keto-DOG; 3-Oxodesogestrel; Implanon; Implanon NXT; MK-8415; Nexplanon; Org 32222; ORG-3236; SCH900415

Latest Information Update: 06 May 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Organon
  • Developer Merck & Co; Pharmaco (NZ); Schering-Plough
  • Class Hormonal contraceptives; Norpregnanes; Phenanthrenes; Progesterone congeners; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pregnancy

Most Recent Events

  • 19 Nov 2020 Phase-III clinical trials in Pregnancy (Prevention) in Puerto Rico (Intradermal) (NCT04626596)
  • 19 Nov 2020 Merck initiates enrolment in the phase III trial for Pregnancy (Prevention) in USA (Intradermal) (NCT04626596)
  • 12 Nov 2020 Merck Sharp & Dohme plans the phase III MK-8415-060 trial in Pregnancy (Prevention) in November 2020 (Intradermal, Implant) (NCT04626596)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top